New developments in the clinical use of drug-coated balloon catheters in peripheral arterial disease

Jesse Naghi
Ethan A Yalvac
Ali Pourdjabbar
Lawrence Ang
John Bahadorani
Ryan R Reeves
Ehtisham Mahmud
Mitul Patel

Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California, San Diego, CA, USA

Abstract: Peripheral arterial disease (PAD) involving the lower extremity is a major source of morbidity and mortality. Clinical manifestations of PAD span the spectrum from lifestyle limiting claudication to ulceration and gangrene leading to amputation. Advancements including balloon angioplasty, self-expanding stents, drug-eluting stents, and atherectomy have resulted in high technical success rates for endovascular therapy in patients with PAD. However, these advances have been limited by somewhat high rates of clinical restenosis and clinically driven target lesion revascularization. The recent introduction of drug-coated balloon technology shows promise in limiting neointimal hyperplasia induced by vascular injury after endovascular therapies. This review summarizes the contemporary clinical data in the emerging area of drug-coated balloons.

Keywords: drug-coated balloons, endovascular, percutaneous transluminal angioplasty, paclitaxel, peripheral arterial disease

Introduction

Peripheral arterial disease (PAD) of the lower extremity is a major source of morbidity and mortality. Historically, bypass surgery has been the primary method of revascularization for symptomatic patients; however, improvements in efficacy and safety of catheter-based, endovascular interventions have led to a transition to the latter approach becoming the first-line therapy in a variety of anatomic and pathologic scenarios.1 The contemporary strategies available for treatment of disease involving the femoropopliteal axis include percutaneous transluminal angioplasty (PTA), atherectomy, and stent implantation. Despite a high initial success rate of up to 95%, each of these options has been limited by unfortunately high rates of vessel restenosis, which ranges from 40% to 60% in standard PTA and 25% to 40% in stent procedures over 12 months.2–12 Limited data regarding implantation of a paclitaxel-eluting nitinol stent have suggested a benefit in terms of restenosis rates.13–17 Despite this, the concern for stent fracture, although rare, related to dynamic flexion and torsion in the femoropopliteal axis and resultant in-stent restenosis, which can be more challenging to treat, remains a limitation.9,18,19 Thus, an ideal strategy would allow for the deposition of efficacious drug without the need for implantation of a stent platform.

Recently, paclitaxel drug-coated balloons (DCBs) have been developed as a method of homogenous deposition of antiproliferative drug within arteries. When utilized with a carrier molecule, paclitaxel is able to coat a standard angioplasty balloon and is delivered locally to the vessel wall where it remains active for 180 days in order to
limit restenosis. Multiple trials have been conducted evaluating the safety, feasibility, and efficacy of these new devices in the treatment of both above-the-knee and below-the-knee (BTK) de novo atherosclerotic lesions. These studies are presented in this review.

**Femoropopliteal lesions**

De novo atherosclerosis of the femoropopliteal axis is highly prevalent and contributes to both patient morbidity and health care economic strain. Durable endovascular therapy is evolving to improve long-term outcomes and minimize the need for repeat interventions or amputation. The use of DCBs has been studied and appears to provide effective therapy, which is durable, safe, and technically feasible.

The initial trial comparing DCBs to standard PTA was the THUNDER trial. This was a multicenter study, which included 154 patients with symptomatic PAD and ≥1 lesions with ≥70% diameter stenosis in the superficial femoral artery (SFA) or popliteal artery treated between 2004 and 2005. Patients were prospectively randomized to one of three strategies, which were DCB angioplasty with a paclitaxel-coated (P ACCOCATH 3 μg/mm² paclitaxel coating; Braun Melsungen AG, Berlin, Germany) balloon, standard balloon angioplasty (PTA), and standard balloon angioplasty with the use of paclitaxel solution added to the contrast media (P-Contrast). Baseline characteristics were similar between the three groups (Table 1). Importantly, mean Rutherford classification (RC) (DCB 3.4±0.8 vs PTA 3.1±0.8 vs P-Contrast 3.4±1, P=0.71), number of totally occluded vessels (DCB 27% vs PTA 26% vs P-Contrast 27%, P=1), and lesion length (DCB 7.5±6.2 cm vs PTA 7.4±6.7 cm vs P-Contrast 7.4±6.5 cm, P=0.73) were similar. Angioplasty was performed per standard protocol and technically successful in all patients. Repeat angiography was performed at 6 months, and clinical follow-up was conducted at 6, 12, and 24 months. Clinically, all three groups saw functional improvement as evidenced by 6-month RC (DCB 3.4±0.8 to 1.1±1.2 vs PTA 3.1±0.8 to 1.2±1.5 vs P-Contrast 3.4±1.0 to 1.7±1.8, P=0.15). Late lumen loss (LLL) at 6 months (DCB 0.4±1.2 mm vs PTA 1.7±1.8 mm vs P-Contrast 2.2±1.6 mm, P<0.001) and clinically driven target lesion revascularization (CD-TLR) at 6, 12, and 24 months (DCB 4%/10%/15% vs PTA 37%/48%/52% vs P-Contrast 29%/35%/40%, P<0.001) were significantly lower in the DCB group (Table 2). There were no procedural adverse events attributed to the use of DCB and no difference in the rates of target vessel leg amputation or death between the groups. Long-term follow-up was conducted at 5 years in the DCB and PTA groups, which showed that CD-TLR rates remained significantly lower in the DCB group (21% vs 56%, P=0.0005). Binary restenosis (BR) was assessed in a small portion of the study population (n=31) by duplex ultrasound or angiography during this time period and was reported to occur less frequently in the DCB group (17% vs 54%, P=0.04). This initial trial showed in a relatively small cohort that application of paclitaxel to a standard angioplasty balloon could improve restenosis rates as assessed by LLL and CD-TLR up to 2 years post-PTA without compromising procedural safety. Long-term follow-up continued to identify benefit among the DCB-treated group.

A similar trial was conducted by Werk et al, which evaluated 87 patients with symptomatic femoropopliteal disease. Patients were randomized to treatment with standard versus paclitaxel-coated (3 μg/mm²) balloon angioplasty. The primary end point was LLL determined at 6 months by angiography, and the secondary end points were target lesion revascularization (TLR), lesion restenosis, and change in ankle–brachial index (ABI). No significant differences were found in baseline or angiographic characteristics between the two groups. Technical success was obtained in all patients with similar number of stents required in 14% versus 9% of standard balloon and DCB patients, respectively. LLL (0.5±1.1 mm vs 1.0±1.1 mm, P=0.03) and TLR (2.2% vs 33%, P=0.002) were significantly lower in the DCB group. RC was improved to a greater degree in the DCB group versus standard balloon angioplasty, while follow-up ABI did not differ between the groups. This pilot trial further supported the use of paclitaxel-coated balloons for the treatment of femoropopliteal disease.

The LEVANT 1 (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial was a multicenter study, conducted in 2009, of 101 symptomatic patients with ≥1 lesions in the SFA or popliteal artery with ≥70% diameter stenosis and lesions 4–15 cm in length. All patients underwent predilation with a standard balloon per institutional protocol. They were then categorized as balloon only or stent cohorts based on the presence of ≥70% residual stenosis or flow-limiting dissection. Each group of patients was then randomized to DCB (Lutonix 2 μg/mm² paclitaxel coating with polysorbate/sorbitol carrier; BARD PV, Tempe, AZ, USA) or PTA in a 1:1 fashion. The primary end point was angiographic 6-month LLL. Secondary outcomes included functional improvement and primary patency (freedom from CD-TLR or BR) at 1, 6, 12, and 24 months. Baseline characteristics were again well-matched and represented real-world cases with the majority of cases having RC 3 (DCB 72% vs PTA 71%, P=0.8), mean lesion length (DCB 80.8±37 mm
### Table 1 Baseline clinical and angiographic measures for femoropopliteal studies

<table>
<thead>
<tr>
<th>Trial</th>
<th>Enrollment period</th>
<th>Patients randomized (n)</th>
<th>DCB Inclusion criteria</th>
<th>DCB Exclusion criteria</th>
<th>Follow-up period</th>
<th>Outcomes measured</th>
<th>Baseline RC (%)</th>
<th>Total occlusions (%)</th>
<th>Lesion length (mm)</th>
<th>Stent placement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>THUNDER 24</td>
<td>2004–2005</td>
<td>102 (48 DCB vs 54 PTA)</td>
<td>Standard balloons coated with paclitaxel (PACCOCATH coating) (3 μg/mm² balloon surface)</td>
<td>One vessel with &gt;70% stenosis, &gt;2 cm length in SFA/Pop</td>
<td>Poor inflow, No outflow, acute presentation, pregnancy, life expectancy &lt;1 year</td>
<td>6-month angiogram follow-up</td>
<td>LLL and MAE at 6 months</td>
<td>DCB 3.4; PTA 3.1</td>
<td>DCB 27%; PTA 26%</td>
<td>DCB 7.5 cm; PTA 7.4 cm</td>
</tr>
<tr>
<td>THUNDER 25</td>
<td>2004–2005</td>
<td>102 (48 DCB and 54 PTA) of which 30 patients had 5-year follow-up data</td>
<td>Standard balloons coated with paclitaxel (PACCOCATH coating) (3 μg/mm² balloon surface)</td>
<td>One vessel with &gt;70% stenosis, &gt;2 cm length in SFA/Pop</td>
<td>Poor inflow, No outflow, acute presentation, pregnancy, life expectancy &lt;1 year</td>
<td>2–5 years postoperative clinical follow-up</td>
<td>TLR</td>
<td>DCB 3.4; PTA 3.1</td>
<td>DCB 27%; PTA 26%</td>
<td>DCB 7.5 cm; PTA 7.4 cm</td>
</tr>
<tr>
<td>LEVANT 1</td>
<td>2009–2009</td>
<td>75 randomized to DCB vs PTA after standard angioplasty</td>
<td>Lutonix (2 μg/mm² balloon surface polysorbate/sorbitol)</td>
<td>Symptomatic with one lesion &gt;70% stenosis, 4–15 cm in length, vessel diameter 4–6 cm</td>
<td>Severe calcification, inflow disease, or absence of ≥1 runoff vessel</td>
<td>1, 6, 12, and 24-month clinical follow-up. Angiogram at 6 months</td>
<td>LLL at 6 months, CD-TLR at 1, 6, 12, and 24 months</td>
<td>DCB 2/3/4/5; PTA 22%/72%/2%/4%</td>
<td>DCB 41%; PTA 42%</td>
<td>DCB 80.8±37.0 mm; PTA 80.2±37.8 mm</td>
</tr>
<tr>
<td>LEVANT 2</td>
<td>2011–2012</td>
<td>476 randomized 2:1 to DCB vs PTA</td>
<td>Lutonix (2 μg/mm² balloon surface polysorbate/sorbitol)</td>
<td>Symptomatic claudication, RC 2–4 with &gt;70% stenosis in SFA or Pop length &lt;15 cm and diameter 4–6 cm</td>
<td>Need for stent post predilation angioplasty</td>
<td>1, 6, and 12-month clinical follow-up</td>
<td>Primary patency, death, amputation</td>
<td>DCB 2/3/4; DCB 29%/63%/8%; PTA 34%/58%/8%</td>
<td>DCB 21%; PTA 21.9%</td>
<td>DCB 62.7±1 mm; PTA 63.2±40.4 mm</td>
</tr>
<tr>
<td>DEBATE-SFA</td>
<td>2010–2011</td>
<td>104 randomized to DCB + BMS or PTA + BMS</td>
<td>IN.PACT Admiral (3 μg/mm² balloon surface) and urea as hydrophilic natural spacer</td>
<td>Claudication with &gt;70% stenosis, &gt;4 cm length in SFA/Pop with at least one patent infrapopliteal vessel</td>
<td>Life expectancy &lt;1 year, preprocedure need for amputation</td>
<td>12-month angiogram</td>
<td>Binary restenosis by angiogram or US PSV ratio &gt;2.4 (primary) and TLR (secondary)</td>
<td>DCB 3/4/5/6; DCB 21/21/55/49%; PTA 31/22/41/696</td>
<td>DCB 55%; PTA 69%</td>
<td>DCB 94 mm; PTA 96 mm</td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Enrollment period</th>
<th>Patients randomized (n)</th>
<th>DCB</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Follow-up period</th>
<th>Outcomes measured</th>
<th>Baseline RC</th>
<th>Total occlusions</th>
<th>Lesion length</th>
<th>Stent placement</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACIFIER⁵⁵</td>
<td>2010–2012</td>
<td>85: 44 DCB vs 41 Pacific</td>
<td>Claudication with &gt;70% stenosis of SFA/Pop, length 3–30 cm</td>
<td>Inflow disease, significant three-vessel infraopiletal disease</td>
<td>6-month angiogram. 6 and 12-month clinical follow-up. LLL at 6 months. CD-TLR at 6 and 12 months</td>
<td>RC 2/3/4/5; DCB 9%/86%/0%/4.5%; PTA 13%/83%/43%/0%</td>
<td>DCB 22.7%; PTA 38.3%</td>
<td>DCB 7 cm; PTA 6.3 cm</td>
<td>DCB 20.5%; PTA 34%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IN.PACT SFA ¹¹</td>
<td>2010–2013</td>
<td>331 randomized 2:1 DCB vs PTA</td>
<td>RC 2–4, &gt;70% stenosis of SFA/Pop, 4–18 cm if no occlusion, &lt; 10 cm if total occlusion</td>
<td>Inflow disease, significant three-vessel infraopiletal disease</td>
<td>1, 6, and 12-month clinical follow-up. Primary patency at 12 months</td>
<td>RC 2/3/4/5; DCB 38%/57%/5%/0%; PTA 38%/56%/5%/1%</td>
<td>DCB 25.8%; PTA 19.5%; P = 0.22</td>
<td>DCB 8.94±4.89 cm; PTA 8.81±5.12 cm</td>
<td>DCB 7.3%; PTA 12.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IN.PACT SFA</td>
<td>2 year³³</td>
<td>331 randomized 2:1 DCB vs PTA</td>
<td>RC 2–4, &gt;70% stenosis of SFA/Pop, 4–18 cm if no occlusion, &lt; 10 cm if total occlusion</td>
<td>Inflow disease, significant three-vessel infraopiletal disease</td>
<td>12- to 24-month clinical follow-up. Primary patency, freedom from CD-TLR</td>
<td>RC 2/3/4/5; DCB 38%/57%/5%/0%; PTA 38%/56%/5%/1%</td>
<td>DCB 25.8%; PTA 19.5%; P = 0.22</td>
<td>DCB 8.94±4.89 cm; PTA 8.81±5.12 cm</td>
<td>DCB 7.3%; PTA 12.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIOLUX-P1³⁴</td>
<td>2010–2011</td>
<td>60 patients randomized 1:1 DCB vs PTA</td>
<td>RC 2–5, &gt;70% stenosis of SFA/Pop, 3–20 cm lesion length</td>
<td>Thrombus present, &lt; 1 patent infraportal vessel, prior stent at target lesion, prior bypass graft, severe calcification</td>
<td>6-month angiogram. 6 and 12-month clinical follow-up. Primary – LLL at 6 months Secondary – BR at 6 and 12 months</td>
<td>RC 2/3/4/5; DCB 23%/57/13/7; PTA 30/57/77</td>
<td>38.2% of entire cohort</td>
<td>DCB 51.4±47.2 mm; PTA 68.5±57.0 mm; P = 0.038</td>
<td>DCB 6.7%; PTA 26.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Primary patency, freedom from binary restenosis by US or TLR.
Abbreviations: BMS, bare metal stent; BR, binary restenosis; BTHC, n-butyryl-tri-n-hexyl citrate; CD-TLR, clinically driven target lesion revascularization; DCB, drug-coated balloon; LLL, late lumen loss; MAE, major adverse event; Pop, popliteal artery; PSV, peak systolic velocity; PTA, percutaneous transluminal angioplasty; RC, Rutherford classification; SFA, superficial femoral artery; TLR, target lesion revascularization; US, ultrasound.
vs PTA 80.2±37.8 mm, *P*=0.89), and total occlusion rate (DCB 41% vs PTA 42%, *P*=0.88) (Table 1). Device success was notably lower in the DCB group compared with PTA, as there were eight device malfunctions, which resulted in an inability to deposit adequate drug at the lesion site. This device-related issue was related to twisted folds in the balloon itself, which prevented inflation and was corrected early on in the trial with no further malfunctions noted. Despite the lower technical success rate, LLL at 6 months was significantly lower in the DCB group (DCB 0.46±1.13 mm vs PTA 1.09±1.07 mm, *P*=0.016). Primary patency (DCB 57% vs PTA 40%, *P*=0.05) and CD-TLR (DCB 36% vs PTA 49%, *P*=0.05) at 24 months were similar between the two groups. ABI and RC were notably improved from baseline in both the groups to 24 months. Composite major adverse events (MAEs) (death, thrombosis, amputation, reintervention) occurred in 39% of the DCB cohort and 46% of the PTA cohort (*P*=0.45) (Table 2). In the LEVANT 1 trial, long-term clinical equipoise was noted between the Lutonix DCB and standard balloon angioplasty despite a significant difference observed in LLL. This result may have been influenced by the early occurrence of device malfunction as freedom from CD-TLR, and primary patency rates between the successful and failed DCB patients were significantly lower. Further studies evaluating the Lutonix DCB were recommended.

Based on the results from the LEVANT 1 trial, the Lutonix balloon was further evaluated in a large multicenter setting. The LEVANT 2 trial enrolled 543 patients with

<table>
<thead>
<tr>
<th>Trial</th>
<th>Primary patency</th>
<th>LLL</th>
<th>RC improvement at follow-up</th>
<th>ABI change</th>
<th>BR</th>
<th>TLR</th>
<th>MAE</th>
</tr>
</thead>
<tbody>
<tr>
<td>THUNDER 5 years</td>
<td>NA</td>
<td>DCB 0.4±1.2 mm; PTA 1.7±1.8 mm; <em>P</em>&lt;0.001</td>
<td>DCB 1.2; PTA 1.6; <em>P</em>&lt;0.02</td>
<td>DCB 0.9; PTA 0.8; <em>P</em>&lt;0.07</td>
<td>DCB 17%; PTA 44%; <em>P</em>&lt;0.01</td>
<td>12/24 months; DCB 10%; PTA 48%; <em>P</em>&lt;0.0001</td>
<td>None</td>
</tr>
<tr>
<td>LEVANT1</td>
<td>NA</td>
<td>DCB 0.7±1.5 mm; PTA 1.5±1.3 mm; <em>P</em>&lt;0.54</td>
<td>NA</td>
<td>NA</td>
<td>DCB 17%; PTA 54%; <em>P</em>&lt;0.04</td>
<td>12/24 months; DCB 13%; PTA 24%; <em>P</em>&lt;0.01</td>
<td>None</td>
</tr>
<tr>
<td>LEVANT2</td>
<td>DCB 65.2%; PTA 52.6%; <em>P</em>&lt;0.02</td>
<td>12 months; DCB 1.9; PTA 1.7; <em>P</em>&lt;NS</td>
<td>12 months; DCB 0.17; PTA 0.18; <em>P</em>&lt;NS</td>
<td>DCB 62%; PTA 65%; <em>P</em>&lt;NS</td>
<td>12 months; DCB 12%; PTA 37%; <em>P</em>&lt;NS</td>
<td>DCB 16%; PTA 21%; <em>P</em>&lt;NS</td>
<td>None</td>
</tr>
<tr>
<td>DEBATE-SFA</td>
<td>NA</td>
<td>DCB 0.86 mm; PTA 1.68 mm; <em>P</em>&lt;0.001</td>
<td>RC delta ≥2; DCB 81.8%; PTA 54.5%; <em>P</em>&lt;0.02</td>
<td>NA</td>
<td>DCB 17%; PTA 47.3%; <em>P</em>&lt;0.008</td>
<td>12 months; DCB 17%; PTA 33%; <em>P</em>&lt;0.07</td>
<td>None</td>
</tr>
<tr>
<td>PACIFIER</td>
<td>NA</td>
<td>DCB −0.01 mm; PTA 0.65 mm; <em>P</em>&lt;0.001</td>
<td>Improvement in RC ≥1; DCB 80%; PTA 68%</td>
<td>NA</td>
<td>DCB 8.6%; PTA 32.4%; <em>P</em>&lt;0.01</td>
<td>6/12 months; DCB 71.7%; PTA 26.2%; <em>P</em>&lt;0.01</td>
<td>Death, amputation, TLR; DCB 7.1%; PTA 34.9%; <em>P</em>&lt;0.003</td>
</tr>
<tr>
<td>IN.PACT SFA</td>
<td>DCB 82.2%; PTA 52.4%; <em>P</em>&lt;0.001</td>
<td>Sustained clinical improvement; DCB 85%; PTA 67%; <em>P</em>&lt;0.001</td>
<td>DCB 0.95; PTA 0.89; <em>P</em>&lt;0.002</td>
<td>NA</td>
<td>DCB 2.4%; PTA 20.6%; <em>P</em>&lt;0.001</td>
<td>DCB 10%; PTA 48%; <em>P</em>&lt;0.001</td>
<td>Safety composite: DCB 87.4%; PTA 69.4%; <em>P</em>&lt;0.001; MAE: DCB 19.2%; PTA 31.1%; <em>P</em>&lt;0.02</td>
</tr>
<tr>
<td>IN.PACT SFA 2 years</td>
<td>DCB 78.9%; PTA 50.1%; <em>P</em>&lt;0.001</td>
<td>Sustained clinical improvement; DCB 77%; PTA 59%; <em>P</em>&lt;0.003</td>
<td>DCB 0.92; PTA 0.94; <em>P</em>&lt;0.011</td>
<td>DCB 19.8%; PTA 46.9%; <em>P</em>&lt;0.01</td>
<td>DCB 9.1%; PTA 28.3%; <em>P</em>&lt;0.001</td>
<td>DCB 15.4%; PTA 41.7%; <em>P</em>&lt;0.06</td>
<td>DCB 19.2%; PTA 41.2%; <em>P</em>&lt;0.14</td>
</tr>
<tr>
<td>BIOLUX-P14</td>
<td>NA</td>
<td>DCB 0.5±0.7 mm; PTA 1.0±1.0 mm; <em>P</em>&lt;0.033</td>
<td>RC improvement at follow-up; DCB 1%; PTA 1%</td>
<td>DCB 0.9±0.2; PTA 1.0; <em>P</em>&lt;NS</td>
<td>DCB 11.5%; PTA 34.6%; <em>P</em>&lt;0.048</td>
<td>DCB 15.4%; PTA 41.7%; <em>P</em>&lt;0.06</td>
<td>DCB 19.2%; PTA 41.2%; <em>P</em>&lt;0.14</td>
</tr>
</tbody>
</table>

**Note:** Primary patency, freedom from binary restenosis by US or TLR.

**Abbreviations:** ABI, ankle–brachial index; BR, binary restenosis; DCB, drug-coated balloon; LLL, late lumen loss; MAE, major adverse event; NA, not available; NS, not significant; PTA, percutaneous transluminal angioplasty; RC, Rutherford classification; SFA, superficial femoral artery; TLR, target lesion revascularization; US, ultrasound.
symptomatic claudication and ≥1 lesions in the SFA or popliteal artery of ≥70% diameter stenosis in a 4–6 mm vessel with a total length of <15 cm. All patients in this trial underwent lesion predilation with a standard balloon, and if no need for stenting (ie, flow-limiting dissection or residual stenosis >70%) was found, they were randomized in a 2:1 fashion to DCB with the Lutonix balloon or PTA. Four hundred and seventy-six patients were randomized to DCB versus PTA with respective procedural success rates of 88.9% and 86.8%, P=0.5. Baseline characteristics were well-matched, and percent RC 3 (62.7% vs 57.5%), lesion length (62.7±41.4 mm vs 63.2±40.4 mm), and total occlusions (20.6% vs 21.9%) were similar between the DCB and PTA groups (Table 1). Primary patency was evaluated at 12 months and was found to be significantly better in the DCB group (65.2% vs 52.6%, P=0.02). CD-TLR occurred at similar rates between the DCB and PTA groups (12.3% vs 16.8%, P=0.21). The primary safety measure was a composite of freedom from periprocedural death and freedom at 12 months from index limb amputation, index limb revascularization, and index limb-related amputation occurred at similar rates between the groups (83.9% vs 79.0%), and the DCB met noninferiority criterion with regard to safety (Table 2). The LEVANT 2 trial showed promising results in terms of safety and efficacy in terms of primary patency at 1-year follow-up. Despite this, rates of CD-TLR remained similar between the two groups. This may be related to an unexpectedly lower rate of CD-TLR in the PTA group than previously studies, and long-term follow-up is underway to further evaluate this cohort.

Based on the data from the initial THUNDER trial, a similar paclitaxel-coated balloon was developed with the use of urea as the carrier molecule to enhance homogenous delivery (FreePac®; Medtronic, Santa Rosa, CA, USA). The first balloon evaluated with this new coating was studied in the PACIFIER trial.20 Subjects were enrolled if they had RC 2–5 and ≥1 lesions in the SFA or popliteal artery with ≥70% diameter stenosis, which was 3–30 cm in length. Randomization was performed in 85 patients who met criteria after successful wiring of the lesion in a 1:1 fashion to DCB (IN.PACT Pacific paclitaxel-coated 3 μg/mm² balloon; Medtronic) or PTA (Pacific Xtreme balloon; Medtronic). Of note, only 13.6% of patients underwent predilation with a standard balloon in the DCB group. Clinically, the DCB and PTA groups were similar with regard to RC 3 (86.4% vs 83%), lesion length (70±33 mm vs 66±55 mm), and total occlusions (22.7% vs 38.3%), respectively (Table 1). The primary efficacy end point of mean LLL at 6 months was significantly better in the DCB group (−0.01 mm vs 0.65 mm, P=0.001). Interestingly, the authors reported that lesions with larger degree residual stenosis post DCB were more likely to see lower LLL or even positive remodeling, which they speculated to be secondary to the antiproliferative effects of paclitaxel and plaque regression. BR rates were lower in the DCB group at 6 months (8.6% vs 32.4%, P=0.01). Improvement in RC was observed in numerically but not statistically more of the DCB patients (80% vs 68.4%, P=0.36). MAE (death, amputation, or CD-TLR) at 12 months was significantly lower in the DCB group (7.1% vs 34.9%, P=0.003), which was largely driven by less CD-TLR (7.1% vs 27.9%, P=0.02) (Table 2). The PACIFIER trial showed excellent efficacy and safety rates for the novel paclitaxel-coated IN.PACT balloon and interestingly a mean LLL, which suggested positive remodeling of the vessel after DCB.

While the use of PTA is generally the first strategy for the treatment of the femoropopliteal axis, stent deployment is frequently necessary in complex lesions. Restenosis rates remain high with bare metal stents (BMSs) and are ameliorated with drug-eluting stents (DESs).14,30 These findings have raised the question as to whether it is the drug itself, the polymer, or the scaffold that is responsible for improvement in long-term results. To further evaluate the effect of DCBs in the setting of complex femoropopliteal lesions with a planned bare metal nitinol stent (Maris stent, Invatec; Medtronic) implantation strategy, the DEBATE-SFA trial was conducted.11 This trial randomized 104 patients with symptomatic PAD (claudication and critical limb ischemia [CLI]) and complex lesions (lesion length DCB 94±60 mm vs PTA 96±69 mm, P=0.5; total occlusions DCB 54.5% vs PTA 69.1%, P=0.1; severe calcification DCB 22% vs PTA 20%, P=0.8) to DCB+BMS (IN.PACT Admiral Balloon) or PTA+BMS in a 1:1 fashion (Table 1). Technical and procedural success was 100% in both groups. Patients were evaluated at 12 months either angiographically or by Doppler ultrasound (DUS) for BR, which was significantly lower in the DCB + BMS patients (7.3% vs 17%, P=0.008). This finding held true even among patients with very long lesions (≥100 mm) (21% vs 62%, P=0.01) and patients who achieved recanalization via a subintimal dissection and reentry approach (0% vs 47.1%, P=0.01). The secondary end point of freedom from CD-TLR at 12 months trended toward benefit in the DCB + BMS group (DCB 83% vs PTA 66.7%, P=0.07). Of the patients evaluated by angiography, LLL at 12 months was significantly lower in the DCB group (0.86 mm vs 1.68 mm, P<0.001). Additionally, RC improvement ≥2 was observed more often in the DCB group
For personal use only.

24 months follow-up (9.1% vs 28.3%, \( P < 0.001 \)) for the intention-to-treat population and 16.0% vs 52.9% \( P = 0.020 \) for the as-treated population. No death and one minor amputation were observed compared with two deaths and two minor amputations in the control group. No major amputations or thrombosis were reported. Similarly, the novel low drug dose Stellarex DCB (2 μg/mm² balloon surface and polyethylene glycol excipient) was evaluated in a prospective single-arm trial for safety and efficacy.\(^{35}\) In the Illumenate trial, 50 patients with 58 lesions were enrolled and treated with standard PTA followed by DCB with the Stellarex balloon. The primary effectiveness end point was 6-month LLL. The major secondary end point was MAE rate at 6 months, defined as cardiovascular death, amputation, and/or ischemia-driven TLR. Clinical follow-up and Doppler ultrasonography were performed up to 24 months postprocedurally. The primary and secondary end points met their prespecified goals at 6 months, as the MAE rate was 4% and the mean LLL was 0.54 mm. The primary patency rate was 89.5% at 12 months and 80.3% at 24 months. The freedom from CD-TLR was 90.0% at 12 months and 85.8% at 24 months. Additionally, there were no amputations or cardiovascular deaths reported through 24 months. These studies are encouraging as they highlight the efficacy and safety of newer generation DCBs on the horizon.

These trials support the efficacy of DCBs across the spectrum of patients with symptomatic femoropopliteal PAD. Both angiographic and clinical outcomes are markedly improved with utilization of DCB with rates of primary patency ranging from 65% to 90% at 1 year. Although the Lutonix balloon shows significant improvement in primary patency, CD-TLR was similar compared with PTA, which may be related to the choice of drug excipient. The IN.PACT Admiral DCB when compared to PTA in terms of clinical events at up to 24 months follow-up.

Recently, novel DCBs have been developed and tested in small trials for safety and efficacy. The BIOLUX-P1 trial was the first in human trial to evaluate the Passeo-18 Lux DCB (3 μg of paclitaxel/mm²), which is coated with paclitaxel using n-butyltri-n-hexyl citrate (BTHC) (Biotronik AG, Buelach, Switzerland).\(^{34}\) This group randomized 60 patients with symptomatic femoropopliteal arterial disease in a 1:1 fashion to treatment with the Passeo-18 Lux balloon or standard PTA. The primary end point was LLL at 6 months. Secondary end points were BR at 6 months, CD-TLR, change in ABI and RC, and MAEs at 6 and 12 months. At 6 months, patients treated in the DCB group had a significantly lower LLL (0.51±0.72 mm vs 1.04±1.00 mm, \( P = 0.033 \)) and BR (11.5% vs 34.6%, \( P = 0.048 \)) than the PTA group. Additionally, there was a reduction in CD-TLR in the DCB group at 12 months (15.4% vs 41.7% [\( P = 0.064 \)]) for the intention-to-treat population and 16.0% vs 52.9% \( P = 0.020 \) for the as-treated population. No death and one minor amputation were observed compared with two deaths and two minor amputations in the control group. No major amputations or thrombosis were reported. Similarly, the novel low drug dose Stellarex DCB (2 μg/mm² balloon surface and polyethylene glycol excipient) was evaluated in a prospective single-arm trial for safety and efficacy.\(^{35}\) In the Illumenate trial, 50 patients with 58 lesions were enrolled and treated with standard PTA followed by DCB with the Stellarex balloon. The primary effectiveness end point was 6-month LLL. The major secondary end point was MAE rate at 6 months, defined as cardiovascular death, amputation, and/or ischemia-driven TLR. Clinical follow-up and Doppler ultrasonography were performed up to 24 months postprocedurally. The primary and secondary end points met their prespecified goals at 6 months, as the MAE rate was 4% and the mean LLL was 0.54 mm. The primary patency rate was 89.5% at 12 months and 80.3% at 24 months. The freedom from CD-TLR was 90.0% at 12 months and 85.8% at 24 months. Additionally, there were no amputations or cardiovascular deaths reported through 24 months. These studies are encouraging as they highlight the efficacy and safety of newer generation DCBs on the horizon.
Infrapopliteal disease and CLI

CLI is the salient clinical stage of progressive PAD and often an earmark of broader systemic atherosclerosis. Patients present with symptoms of resting claudication, nonhealing ulceration, and if left untreated, gangrene. RC 4–6 are the descriptive surrogates for these three stages and are typically associated with an ABI <0.4. Physiologically, CLI is explained by the mismatch of arterial perfusion and metabolic demand leading to reduced tissue oxygen tension and cellular injury. Nearly half of all untreated CLI patients will require major amputation (defined as above the ankle) within 1 year.36,37 Major amputation is associated with reduced quality of life and poor overall survival.38 Today, CLI carries an intermediate-term survival (defined as a 1- to 2-year mortality risk) of ~25%.39 As opposed to significant reductions in mortality with many pathologic processes, mortality from complications of CLI have only mildly diminished over the last 20 years. In 1997, the ICAI Group (Gruppo di Studio dell’Ischemia Cronica Critica degli Arti Inferiori) reported a 31% 2-year mortality in CLI patients.39 A recent multicenter retrospective analysis identified adverse cardiovascular events (eg, myocardial infarction and stroke) as the primary mortality risk (47%) for CLI patients.40 The Bypass versus Angioplasty in Severe Ischemia of the Leg (BASIL) trial randomized CLI patients to either surgery or balloon angioplasty and showed equivalent 12-month (71% vs 68%) and 36-month (52% vs 57%) rates of amputation-free survival, despite lower patency in the angioplasty arm. The 2-year mortality in the BASIL trial was 26.8%.41 These findings highlight the conceptual goals of endovascular revascularization in CLI patients. Long-term vessel patency, although desirable, is less frequently achievable and perhaps unnecessary as even short-term improvement in perfusion and tissue oxygenation facilitates wound healing and limb salvage (LS). Once the higher metabolic needs for wound healing are satisfied, the perfusion demands of the limb are mitigated. This concept suggests that the commonly used end points of angiographic success, LLL, primary patency, and BR, are less likely relevant in the tibial vascular bed. Instead, end points highlighting clinical success such as improvement in RC, freedom from bypass, CD-TLR, and LS should be employed.

Given the remarkable efficacy of DCB technology in above-the-knee interventions, it is not surprising there is great interest and hope for its infrapopliteal application.27,32 However, there are aspects that are unique to BTK pathology. Other than the obvious smaller vessel lumen, infrapopliteal disease is often complex involving long, diffusely stenotic vessels burdened with heavy calcification. In CLI patients, chronic occlusions of at least one if not multiple tibial vessels are usually encountered. Inflow lesions (proximal to the tibial vessels) and/or poor pedal runoff compound the risk for thrombosis and distal embolization. Determination of procedural success can be difficult with variable and difficult to gauge end points. Traditional PTA has become the initial intervention of choice for CLI. In one cohort (average lesion length 184 mm), combined restenosis/occlusion rates at 3 months were reported to be as high as 69%; yet, clinical improvement (improvement in wound healing or RC) was observed in 75.8%. At 15 months, the rate of CD-TLR was 50%; however, LS was an impressive 100%.42 Multiple series corroborate long-term PTA LS rates between 75% and 100% achieved at the expense of increased CD-TLR.41,43,44 Infrapopliteal DCB-facilitated revascularization has been and continues to be studied in the hope of achieving improved outcomes, the need for reintervention and in turn, reduced overall costs. Recent evidence suggests that there may also be a role for infrapopliteal DESs in the management of CLI.45 Nonetheless, there is a relative paucity of randomized controlled evidence exploring the optimal use of DESs in this territory, and stents are generally limited to the proximal aspect of the infrapopliteal vessels. As in our above-the-knee analysis, this review focuses on de novo infrapopliteal atherosclerotic lesions treated with DCB technology.

DCB versus PTA for infrapopliteal disease

In 2011, Schmidt et al46 published the first single-arm prospective trial using DCB to treat long infrapopliteal lesions. The IN.PACT Amphirion (Medtronic) used the same proprietary FreePac coating as the Medtronic IN.PACT Admiral (lipophilic paclitaxel 3 μg/mm² with a hydrophilic urea excipient). In 104 patients, 109 limbs were treated for CLI (82.6%) or severe claudication (17.4%). Baseline mean RC was 4.5 with 64.2% of patients classified as RC 5 (Table 3). The primary end point was angiographic BR (defined as 50% diameter reduction) and assessed 3 months after the initial procedure. Clinical outcomes were assessed at 3 months and 12 months after DCB angioplasty. Clinical improvement was defined as ≥50% reduction of ulcer size/depth or an increase of at least one RC. Secondary outcomes included need for major amputation, target vessel revascularization, and bypass surgery. Predilatation with an uncoated balloon and a diameter at least 0.5 mm smaller than the DCB was performed in all lesions in order to guarantee contact of the DCB and improved drug delivery. DCB inflation time was at...
### Table 3 Baseline clinical and angiographic measures for BTK studies

<table>
<thead>
<tr>
<th>Trial</th>
<th>Enrollment period</th>
<th>No of patients randomized</th>
<th>DCB Inclusion criteria (all CLI)</th>
<th>Exclusion criteria</th>
<th>Follow-up period</th>
<th>Outcomes measured</th>
<th>Baseline RC</th>
<th>Total occlusions</th>
<th>Lesion length (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt et al</td>
<td>2009–2010</td>
<td>Nonrandomized, 104 patients</td>
<td>IN.PACT Amphirion (FreePac coating) (3 μg/mm² balloon surface, urea excipient)</td>
<td>Tibial vessel(s) with &gt;70% stenosis, &gt;8 cm length</td>
<td>NA, not listed</td>
<td>3-month angiographic; 3- and 12-month clinical</td>
<td>4.5</td>
<td>61.90%</td>
<td>173±87</td>
</tr>
<tr>
<td>Debate BTK</td>
<td>2010–2011</td>
<td>132 randomized l:l to DCB vs PTA</td>
<td>IN.PACT Amphirion (FreePac coating) (3 μg/mm² balloon surface, urea excipient)</td>
<td>Diabetes, tibial vessel(s) with &gt;70% stenosis, &gt;4 cm length, with distal runoff&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Allergy to paclitaxel, planned major amputation, life expectancy &lt;1 year</td>
<td>12-month clinical and angiographic (or DUS)</td>
<td>DCB 5.15; PTA 5.09</td>
<td>DCB 77.5%; PTA 82.1%</td>
<td>DCB 129±83; PTA 131±79</td>
</tr>
<tr>
<td>IN. PACT DEEP</td>
<td>2009–2012</td>
<td>358 randomized 2:1 to DCB vs PTA (all clinical cohort, 167 angiographic cohort)</td>
<td>IN.PACT Amphirion (FreePac coating) (3 μg/mm² balloon surface, urea excipient)</td>
<td>Tibial vessel(s) with &gt;70% stenosis, any length, with distal runoff&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inflow lesion &gt;15 cm length, failure to cross TL with 0.014” wire, planned major amputation, failure to obtain &lt;30% postprocedure residual stenosis</td>
<td>1, 6, and 12-month clinical follow-up; ±12-month angiography</td>
<td>CD‑TLR, LLL, primary safety composite</td>
<td>DCB 4.87; PTA 4.85</td>
<td>DCB 38.6%; PTA 45.9%</td>
</tr>
<tr>
<td>BIOLUX P-II</td>
<td>2012–2014</td>
<td>72 randomized 1:1 to DCB vs PTA</td>
<td>Passeo-18 Lux DEB (3 μg/mm² balloon surface, BTHC excipient)</td>
<td>Tibial vessel(s) with &gt;70% stenosis, &gt;3 cm, with distal runoff&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Need for stent postprediction angioplasty</td>
<td>1, 6, and 12-month clinical follow-up; 6-month angiography</td>
<td>CD‑TLR, LLL, primary safety composite</td>
<td>DCB 4.4; PTA 4.4</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

**Notes:**<sup>a</sup> Distal runoff: at least one tibial vessel with runoff to the foot. Target vessel may have direct or collateral runoff.

**Abbreviations:** BR, binary restenosis; BTHC, n-butyltri-n-hexyl citrate; BTK, below the knee; CLI, critical limb ischemia; CD‑TLR, clinically driven target lesion revascularization; DCB, drug-coated balloon; LLL, late lumen loss; NA, not available; PTA, percutaneous transluminal angioplasty; RC, Rutherford classification; TL, target lesion; TVO, target vessel occlusion; DUS, Doppler ultrasound.
least 1 minute, and in the case of flow-limiting dissection or residual stenosis (>30%), a prolonged dilation up to 5 minutes was performed. Mean lesion length was 173±87 mm with 61.9% of target lesions described as total occlusions. Five cases required bailout stenting. Three-month angiographic data were collected from 84 arteries in the 79 treated limbs of 74 patients. Angiographic primary patency persisted in 61 of the 84 treated arteries (72.6%). BR was observed in 27.4% of treated arteries (19.1% restenosis and 8.3% target vessel occlusion). Twelve-month clinical data were drawn from 86 patients with 91 treated limbs. Clinical improvement occurred in 91.2% of these limbs. TLR was performed in 17.3%, and LS was achieved in 95.6% of the CLI patients (Table 4). Complete wound healing occurred in 74.2% of patients with RC 5 classification at baseline. No bypass surgery was performed during the entire study period. There were four unplanned amputations (two minor, two major). A notable observation by the authors was an altered pattern of recurrent disease after DCB therapy. In 60% of restenotic vessels, lesion length was <20% of the original target lesion. They propose that such a pattern of focal restenosis stands in contrast to the experience with uncoated balloons and may have contributed to the impressive clinical outcomes of the study.42 Not surprisingly, randomized controlled trials quickly followed on the heels of this pilot study.

Further evaluation of DCB therapy in BTK disease continued with the DEBATE-BTK trial (Drug-Eluting Balloon in Peripheral Intervention for Below the Knee Angioplasty Evaluation).47 In this randomized, open-label, single-center study, 132 diabetic patients with 158 infrapopliteal lesions were enrolled to compare DCB angioplasty with traditional PTA. As in the previously mentioned study by Schmidt et al,46 the study balloon was the Medtronic IN.PACT Amphirion. Inclusion criteria were diabetes mellitus, CLI (RC ≥4), stenosis or occlusion >40 mm of at least one BTK vessel with distal runoff, and life expectancy >1 year. The primary end point was binary in-segment restenosis at 12 months as assessed by angiography or DUS. Restenosis was defined as >50% reduction in luminal diameter by angiography or a peak systolic velocity ratio >2.5 by DUS. Secondary end points were CD-TLR, major amputation, and target vessel occlusion. Patient characteristics were statistically well matched. Mean RC at baseline was 5.15 and 5.09 in the DCB and PTA cohorts, respectively. CLI with RC ≥5 was present in 97.2% of DCB patients and 95.8% of PTA patients. Mean ABIs at baseline were 0.31 (DCB) and 0.29 (PTA). Standard balloon predilatation was mandatory prior to DCB dilatation. To avoid geographic miss, radiopaque rulers were used to ensure the DCB treatment zone extended 10 mm beyond the proximal and distal predilatation. Inflation

Table 4 Primary and secondary outcomes for BTK studies

<table>
<thead>
<tr>
<th>Trial</th>
<th>Primary patency</th>
<th>LLL (mm)</th>
<th>BR</th>
<th>Clinical improvement or RC at follow-up</th>
<th>ABI</th>
<th>TLR</th>
<th>MAEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt et al46</td>
<td>3 months:</td>
<td>NA</td>
<td>27.4%; 19.1% restenosis</td>
<td>Clinical improvement 91.2%, complete wound healing 74.2% of RC 5 patients</td>
<td>NA</td>
<td>17.3%</td>
<td>Four amputations (two major, two minor)</td>
</tr>
<tr>
<td>(Single Center Leipzig Registry)</td>
<td>72.6%</td>
<td></td>
<td>and 8.3% target vessel occlusion</td>
<td>DCB: 0.90±1.8; PTA: 2.0±2.3 (P&lt;0.001)</td>
<td>DCB: 0.78±0.22; PTA: 0.47±0.28</td>
<td>DCB: 18%; PTA: 43% (P&lt;0.002); TVO–DCB: 17% (P&lt;0.001); CD-TLR: 12-month primary safety composite – DCB: 17.7%; PTA: 15.8%; 12-month major amputation – DCB: 8.8%; PTA: 3.6%</td>
<td></td>
</tr>
<tr>
<td>Debate BTK47</td>
<td>NA</td>
<td>NA</td>
<td>Clinical improvement 91.2%, complete wound healing 74.2% of RC 5 patients</td>
<td>DCB: 0.90±1.8; PTA: 2.0±2.3 (P&lt;0.001)</td>
<td>DCB: 0.78±0.22; PTA: 0.47±0.28</td>
<td>DCB: 18%; PTA: 43% (P&lt;0.002); TVO–DCB: 17% (P&lt;0.001); CD-TLR: 12-month primary safety composite – DCB: 17.7%; PTA: 15.8%; 12-month major amputation – DCB: 8.8%; PTA: 3.6%</td>
<td></td>
</tr>
<tr>
<td>IN.PACT DEEP48</td>
<td>NA</td>
<td>NA</td>
<td>DCB: 41.0%; PTA: 35.5%</td>
<td>DCB: 0.61±0.78 mm; PTA: 0.62±0.78 mm (P=0.950)</td>
<td>DCB: 0.78±0.22; PTA: 0.47±0.28</td>
<td>DCB: 18%; PTA: 43% (P&lt;0.002); TVO–DCB: 17% (P&lt;0.001); CD-TLR: 12-month primary safety composite – DCB: 17.7%; PTA: 15.8%; 12-month major amputation – DCB: 8.8%; PTA: 3.6%</td>
<td></td>
</tr>
<tr>
<td>BIOLUX P-II19</td>
<td>DCB: 65.2%; P=0.02</td>
<td>DCB: 53.1%; P=0.359</td>
<td>DCB: 2.3±2.3; P=0.05</td>
<td>DCB: 1.0±0.2; PTA: 0.9±0.2 (P=0.327)</td>
<td>DCB: 18%; PTA: 43% (P&lt;0.002); TVO–DCB: 17% (P&lt;0.001); CD-TLR: 12-month primary safety composite – DCB: 17.7%; PTA: 15.8%; 12-month major amputation – DCB: 8.8%; PTA: 3.6%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ABI, ankle–brachial index; BR, binary restenosis; BTK, below-the-knee; CD-TLR, clinically driven target lesion revascularization; DCB, drug-coated balloon; LLL, late lumen loss; MAE, major adverse event; NA, not available; POBA, plain old balloon angioplasty; PTA, percutaneous transluminal angioplasty; RC, Rutherford classification; TLR, target lesion revascularization; TVO, target vessel occlusion.
time was at least 2 minutes for both DCB and PTA arms. In case of flow-limiting dissection or residual stenosis >30%, prolonged dilatation up to 3 minutes was performed. Lesion characteristics and complexity were statistically well matched (Table 3). Average lesion length was 129±83 mm (DCB) and 131±79 mm (PTA). In both groups, ~80% of lesions were total occlusions and 25% were heavily calcified. Subintimal recanalization techniques were utilized in 20% of patients in both study arms, and ~50% of patients underwent inflow lesion treatment during the index procedure. Of the 124 patients alive at 12 months, angiograms were available for 67 of 74 (91%) and 68 of 74 (92%) eligible lesions in the DCB and PTA arms, respectively. The primary endpoint, 12-month BR, occurred in 20 (27%) and 55 (75%) lesions in the DCB and PTA groups, respectively (P<0.001). Target vessel occlusion with DCB occurred in 13 (17%) versus 41 (55%; P<0.001) lesions in the standard PTA group. As anecdotally noted by Schmidt et al,46 occlusion lengths were >95 mm vs 102±91 mm in the PTA arm versus the DCB arm (P=0.002). This held true in the 167-patient angiography cohort with mean lesion lengths of 59.±41.7 mm and 79.7±74.6 mm (P=0.060) and total occlusion present in 31.6% and 32.7% (P=1.00) within the DCB versus PTA treatment arms, respectively. By core laboratory evaluation, wound area was comparable between the two groups but wound depth was significantly less in the DCB versus PTA arms (0.8±1.3 mm vs 1.8±3.8 mm; P=0.040). Professional wound care was received by 62.2% of DCB patients and 52.1% of PTA patients (P=0.087).

Regarding procedural characteristics, predilatation was performed in 90.5% of DCB-treated lesions and 36.0% of PTA-treated lesions (P<0.001). Complete index ulcer healing, 9% (DCB) and ~67% (PTA; P=0.01), as well as average time to index ulcer healing, 4.4 months (DCB) and 5.2 months (PTA; P=0.01), were also significantly different (Table 4). With such findings, DEBATE-BTK appeared as a resounding attestation for DCB therapy in infrapopliteal disease. However, there are caveats that must be highlighted. More than any other study, DEBATE-BTK offered a post-procedure outpatient wound care clinic not often seen in the real world. Patients were seen twice a week for 2 months, then once a week for a month, and then biweekly thereafter. Undoubtedly, such rigorous wound care follow-up maximized the clinical benefit of intervention. This is supported by the equivalent rates of LS found in both DCB and PTA arms. Additionally, patients were enrolled only after successful wiring of the target vessel, and LS rates cannot be compared to studies designed on an intention-to-treat basis. Further, the study was unblinded. Despite these considerations, a statistical benefit was maintained between DCB- versus PTA-treated lesions and ultimately fueled larger prospective trials.

The IN.PACT Amphirion DCB was put to the test with the Drug-Eluting Balloon Versus Standard Balloon Angioplasty of Infrapopliteal Arterial Revascularization in Critical Limb Ischemia (IN.PACT DEEP) trial.48 This was a prospective, multicenter, randomized-controlled trial with independent clinical event adjudication (blinded angiographic and wound core laboratories) that randomized 358 CLI patients 2:1 to DCB or PTA. The two co-primary efficacy end points were CD-TLR and LLL. The primary safety end point through 6 months was a composite of all-cause mortality, major amputation, and CD-TLR. All subjects were followed as a clinical cohort, and 167 subjects were studied in an angiographic cohort. Baseline patient, angiographic, and wound characteristics were well matched with a few exceptions (Table 3). The majority of patients were of RC 5 (84.1% DCB and 77.3% PTA) with an average ABI of 0.75 and 0.81, respectively. Impaired inflow was significantly higher in the DCB arm (40.7%) versus the PTA arm (28.8%; P=0.035). In contrast, target lesions were longer (129±95 mm vs 102±91 mm) in the PTA arm versus the DCB arm (P=0.002). This held true in the 167-patient angiography cohort with mean lesion lengths of 59.±41.7 mm and 79.7±74.6 mm (P=0.060) and total occlusion present in 31.6% and 32.7% (P=1.00) within the DCB versus PTA treatment arms, respectively. By core laboratory evaluation, wound area was comparable between the two groups but wound depth was significantly less in the DCB versus PTA arms (0.8±1.3 mm vs 1.8±3.8 mm; P=0.040). Professional wound care was received by 62.2% of DCB patients and 52.1% of PTA patients (P=0.087). Regarding procedural characteristics, predilatation was performed in 90.5% of DCB-treated lesions and 36.0% of PTA-treated lesions (P<0.001). Direct revascularization to the wound-related artery was performed in 35.6% of patients in the DCB arm and 43.7% of patients in the PTA arm (P=0.166). Procedural complications in aggregate were significantly higher in the DCB arm (9.7%) versus the PTA arm (3.4%; P=0.035). However, these complications were successfully managed and not associated with a higher incidence of distal embolization or need for provisional stent implantation. Of note, failure to obtain <30% postprocedure residual stenosis constituted an exclusion criterion for either group. Ultimately, there was no significant difference in the 12-month primary efficacy end points of CD-TLR (11.9% vs 13.5%, P=0.682), LLL (0.61±0.78 mm vs 0.62±0.78 mm, P=0.950), and BR (41% vs 35.5%, P=0.609). The composites of all-cause death, major amputation, and CD-TLR rates through 6 months were 17.7% in the DCB arm and 15.8% in the PTA arm (P=0.021 for noninferiority) (Table 4). That said, a safety signal driven by major amputation at 12 months was observed with rates...
of 8.8% and 3.6% ($P=0.080$) in the DCB and PTA arms. The observed absence of superiority compared to PTA and the adverse safety signal resulted in the sponsor’s decision to prematurely stop the study and withdraw the DCB device from the market. The IN.PACT DEEP trial illustrates the challenges posed by the CLI patient population and the caution needed in our interpretation of earlier, perhaps less rigorous DCB investigations. Nonetheless, the CD-TLR rate (13.5%) and BR (35.5%) at 12 months for the PTA arm of this study represent an unprecedented benchmark that has not been seen in historical data.46,47 Further, guidelines regarding postoperative wound care and decision pathways to amputation were absent in this multicentered protocol introducing some level of variability. Some have postulated that the divergent findings of the IN.PACT Amphirion from that of the IN.PACT Admiral DCB designed for femoropopliteal use may lie in the design of the BTK balloon.49 First, the Amphirion was manually coated with the urea excipient and paclitaxel only after being folded, possibly resulting in nonuniform distribution and unprotected delivery, leaving the paclitaxel coating vulnerable to loss during transit. Further, the material used in the Amphirion when compared to the IN.PACT Admiral differs in its surface energy. A higher surface energy may provide less efficient paclitaxel release after inflation and contact with vessel endothelium. Problems such as these simply highlight the unknowns regarding this technology and the bioengineering variables that may influence the efficacious application of DCB therapy in CLI patients.

With the withdrawal of the Amphirion balloon, there have been new entrants in the BTK DCB market including Biotronik’s Passeo-18 LUX drug-releasing PTA balloon catheter, which was compared to the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries (BIOLUX P-II trial).50 The Passeo-18 Lux DCB varies from the Medtronic Amphirion in that paclitaxel is incorporated into a delivery excipient of BTHC. This was a prospective, multicenter, randomized first-in-man study enrolling 72 patients who were randomized to either the Passeo-18 LUX DEB (Biotronik AG) or Passeo-18 PTA. Clinical follow-up was assessed at 1, 6, and 12 months with angiographic assessment at 6 months. An independent committee adjudicated adverse events, and an independent core laboratory assessed angiographic parameters. The primary safety end point was a composite of 30-day all-cause mortality, major amputation, target lesion thrombosis, and target vessel revascularization. The primary performance end point was 6-month target lesion primary patency (defined as $<50%$ restenosis). Secondary end points were numerous and included BR, LLL, TLR, target vessel revascularization, and MAE at 6 and 12 months and changes in RC. Baseline patient and lesion characteristics were statistically well matched (Table 3). Mean lesion lengths were $113.1\pm88.1$ mm (DCB) and $115\pm86.9$ mm (PTA). The DCB group had statistically less lesions without calcification than the PTA group ($55.9%$ vs $81.6%$; $P=0.018$). Infow lesions were treated in $50%$ of the DCB and $30.6%$ of the PTA groups ($P=0.093$). Predilation was performed in $87.5%$ of DCB lesions and $32.5%$ of PTA lesions ($P<0.001$). The primary safety end point, MAE at 30 days, occurred in $0%$ of the patients in the DCB group versus $8.3%$ of the patients in the PTA group. At 12 months, $41.1%$ (DCB) versus $39.1%$ (PTA) of the patients experienced a MAE and $3.3%$ versus $5.6%$ experienced a major amputation of the target extremity. The primary performance end point, lesion-based patency loss at 180 days, was observed in $17.1%$ of DCB lesions and $26.1%$ of PTA lesions ($P=0.298$). At 12 months, lesion-based patency loss was seen in $50.8%$ of DCB lesions and $45.6%$ of PTA lesions ($P=0.908$). TLR at 12 months was $30.1%$ and $30.6%$ in the DCB and PTA cohorts, respectively. Despite the loss of patency and high TLR rates at 12 months between DCB and PTA, LS rates were high ($96.7%$ vs $94.1%$) in both groups. Further, mean RC improved comparably between the two groups, from $4.5\pm0.9$ at baseline to $2.3\pm2.3$ at 6 months in the DCB arm and from $4.4\pm1.0$ to $2.7\pm2.4$ in the PTA arm (Table 4). This study establishes not only the Passeo-18 LUX DCB safety profile as comparable to PTA in CLI but also its noninferiority regarding primary angiographic and clinical end points. Given its relatively small size, it may have been underpowered to elucidate subtle advantages observed at 6-month follow-up. The study authors suggest that significantly greater baseline calcified DCB lesions may have played a role in reduced drug delivery and efficacy of the balloon. The BIOLUX P-II trial was a well-designed study but highlights some of the challenges facing DCB therapy in BTK intervention.

The enthusiasm surrounding above-the-knee DCB technologies is somewhat bated in the face of the blurry BTK outcomes. As we move forward with designs for future BTK DCBs and their study protocols to investigate efficacy, one of the primary hurdles will be establishing and differentiating concrete clinical end points from that of procedural and angiographic success. The field needs uniformity in study design. The two randomized controlled trials suggest that 12-month CD-TLR, wound healing, RC, and LS are not statistically different between DCB and standard PTA. It is the opinion
of these authors that future studies should prioritize these clinical end points to help differentiate efficacy. At the same time, the pilot registry and DEBATE-BTK studies suggest that DCB-treated lesions may demonstrate shorter lesion length restenosis and occlusion upon follow-up angiography. This raises the question, are there lesion or vessel attributes, which lend themselves to superior DCB outcomes? If so, by which mechanism might a lesion be best modified to achieve these results? Is there a role for adjunct atherectomy? These are difficult questions that we have only recently started to address with ongoing trials. Lastly, what bioengineering and mechanical improvements in balloon, immunomodulation, and excipient design can be made to improve the delivery of active drug to the focus of disease? Undoubtedly, the empirical-based application of DCB technology in CLI, though still in its infancy, remains achievable.

Conclusion

The introduction of DCB therapy for the treatment of both femoropopliteal and infrapopliteal PAD has already impacted the endovascular management of PAD patients. The ongoing evaluation of this technology including long-term outcomes to confirm durability as well as cost-effectiveness data will determine the role this technology plays going forward. Certainly, robust data in the femoropopliteal space comparing DCB to standard angioplasty are serving to supplant standard angioplasty as the definitive treatment. Stronger data at this stage are lacking on the comparison of DCB technology with BMSs and DESs in the femoropopliteal segment. In addition, further investigation is warranted on the effects of combining the various forms of atherectomy with DCB therapy.

On the other hand, somewhat early experience with DCB therapy in the infrapopliteal space has been limited by a lack of uniformity in study end points and studies lacking the power to determine differences in hard clinical end points such as LS rates. Adjuvant atherectomy in this vascular space also has an unclear role at this point. Finally, the introduction of novel drug-delivery excipients such as BTHC require further validation in larger randomized trials, and head-to-head trials of the currently approved DCB catheters are also warranted to move the field forward.

Disclosure

Ehtisham Mahmud serves on the Consulting and Speaker’s Bureau for Abbott Vascular and Global Advisory Board and Speakers Bureau for Medtronic. Mitul Patel serves on the Consulting and Advisory Board for Avinger, Inc. The other authors report no conflicts of interest in this work.

References


